Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

61. Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery

Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Reddy P, Richerson M, Freeman-Bosco L, Dunn A, White C M, Chow M S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients undergoing CABG. Setting The setting was hospital

NHS Economic Evaluation Database.1999

62. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation.

Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. 10486418 1999 09 17 1999 09 17 2013 11 21 0028-4793 341 12 1999 Sep 16 The New England journal of medicine N. Engl. J. Med. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. 871-8 Whether antiarrhythmic drugs improve the rate of successful resuscitation after out-of-hospital cardiac arrest has not been determined in randomized clinical trials. We (...) conducted a randomized, double-blind, placebo-controlled study of intravenous amiodarone in patients with out-of-hospital cardiac arrest. Patients who had cardiac arrest with ventricular fibrillation (or pulseless ventricular tachycardia) and who had not been resuscitated after receiving three or more precordial shocks were randomly assigned to receive 300 mg of intravenous amiodarone (246 patients) or placebo (258 patients). The treatment groups had similar clinical profiles. There was no significant

NEJM1999

63. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure

Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure Piepoli M, Villani G Q, Ponikowski P, Wright A, Flather M D, Coats A J Authors' objectives To evaluate the role of amiodarone in chronic heart failure. Searching Literature was scanned using a 'formal, computer-aided search'. No further (...) details were given. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) of amiodarone with objective and reproducible entry criteria were included. Follow-up periods ranged from 6 months to 6 years. Specific interventions included in the review Amiodarone in doses ranging from 8 mg/day to 1000mg/day was compared with conventional arrythmic therapy, no therapy and placebo. Participants included in the review Patients with the following medical

DARE.1998

64. Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction

Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction Pedretti R F, Migliori G B, Mapelli V, Daniele G, Podrid P J, Tramarin R (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Invasive and non-invasive diagnostic tests and amiodarone treatment after acute myocardial infarction. Type of intervention Diagnosis; treatment. Economic study type Cost-utility

NHS Economic Evaluation Database.1998

65. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials

Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta (...) -analysis of individual data from 6500 patients in randomised trials Amiodarone Trials Meta-Analysis Investigators Authors' objectives To assess the benefits and risks of prophylactic amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure (CHF). Searching The searches were described as a literature review, computerised literature search and discussion with colleagues. A collaborative group of principal investigators was established. Study selection Study designs

DARE.1997

66. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death

Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death Sim I, McDonald K M, Lavori P W, Norbutas C M, Hlatky M A Authors' objectives To assess the effect of amiodarone on mortality, and the impact of differences in patient population and study design on trial outcomes. Searching MEDLINE (...) and BIOSIS Previews were searched for all trials of amiodarone published between January 1985 and March 1997. The references of the retrieved articles and relevant conference proceedings were also examined. Professionals were contacted for additional trials. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) with at least 3 months treatment and follow-up were included. Specific interventions included in the review Amiodarone in doses ranging from 200

DARE.1997

67. Adverse effects of low dose amiodarone: a meta-analysis

Adverse effects of low dose amiodarone: a meta-analysis Adverse effects of low dose amiodarone: a meta-analysis Adverse effects of low dose amiodarone: a meta-analysis Vorperian V R, Havighurst T C, Miller S, January C T Authors' objectives To assess the odds of experiencing adverse effects with low-dose amiodarone therapy when compared with placebo. Searching MEDLINE was searched through 1996 for trials published in all languages. Manual searches of references and review articles were also (...) carried out. Study selection Study designs of evaluations included in the review Double-blind placebo-controlled trials of maintenance amiodarone with a mean follow-up of at least 12 months [A: and presence of an explicit description of adverse effects in both intervention and placebo groups] were included. Crossover designs were excluded. Specific interventions included in the review Maintenance amiodarone (dose of less than or equal to 400 mg/day) and placebo. Participants included in the review

DARE.1997

68. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death

Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death Owens D K, Sanders G D, Harris R A, McDonald K M, Heidenreich P A, Dembitzer A D, Hlatky M A Record Status This is a critical (...) . Study population The study populations were hypothetical cohorts of patients at either high or intermediate risk of sudden cardiac death. The base-case analysis assumed patients were 57 years old and had survived previous cardiac arrest and thus were at high risk of sudden cardiac death. Patients were at risk for ventricular tachycardia or fibrillation, nonarrhythmic cardiac death, noncardiac death, illness or death related to amiodarone, and perioperative morbidity and mortality related to ICDs

NHS Economic Evaluation Database.1997

69. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery.

Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. 9400034 1997 12 18 1997 12 18 2013 11 21 0028-4793 337 25 1997 Dec 18 The New England journal of medicine N. Engl. J. Med. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. 1785-91 Atrial fibrillation occurs commonly after open-heart surgery and may delay hospital discharge. The purpose of this study was to assess the use of preoperative amiodarone as prophylaxis against (...) atrial fibrillation after cardiac surgery. In this double-blind, randomized study, 124 patients were given either oral amiodarone (64 patients) or placebo (60 patients) for a minimum of seven days before elective cardiac surgery. Therapy consisted of 600 mg of amiodarone per day for seven days, then 200 mg per day until the day of discharge from the hospital. The mean (+/-SD) preoperative total dose of amiodarone was 4.8+/-0.96 g over a period of 13+/-7 days. Postoperative atrial fibrillation occurred in 16

NEJM1997

70. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. 9078197 1997 04 17 1997 04 17 2015 06 16 0140-6736 349 9053 1997 Mar 08 Lancet (London, England) Lancet Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial (...) Investigators. 667-74 Ventricular arrhythmias are a major cause of death after myocardial infarction, especially in patients with poor left-ventricular function. Previous attempts to identify and suppress arrhythmias with various antiarrhythmic drugs failed to reduce or actually increase mortality. Amiodarone is a powerful antiarrhythmic drug with several potentially beneficial actions, and has shown benefit in several small-scale studies. We postulated that this drug might reduce mortality in patients

Lancet1997

71. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. 9078198 1997 04 17 1997 04 17 2015 06 16 0140-6736 349 9053 1997 Mar 08 Lancet (London, England) Lancet Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone (...) Myocardial Infarction Arrhythmia Trial Investigators. 675-82 Survivors of acute myocardial infarction with frequent or repetitive ventricular premature depolarisations (VPDs) have higher mortality 1-2 years after the event than those without VPDs. Although there is no therapy of proven efficacy for such patients, previous studies of amiodarone have been encouraging. CAMIAT was a randomised double-blind placebo-controlled trial designed to assess the effect of amiodarone on the risk of resuscitated ventricular

Lancet1997

72. Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide

Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Zarembski D G, Nolan P E, Slack M K, Caruso A C Authors' objectives To compare the efficacies of two antiarrhythmic drug therapies, amiodarone hydrochloride and flecainide acetate, in maintaining normal sinus (...) rhythm in patients with resistant chronic atrial fibrillation. Searching Current Contents: Clinical Practice was reviewed and MEDLINE was searched from January 1983 to August 1993 for English language studies. Bibliographies of identified articles were searched to locate additional articles. Study selection Study designs of evaluations included in the review Prospective clinical trials were included. Specific interventions included in the review Amiodarone hydrochloride and flecainide acetate

DARE.1995

73. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. 7539890 1995 07 13 1995 07 13 2013 11 21 0028-4793 333 2 1995 Jul 13 The New England journal of medicine N. Engl. J. Med. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. 77-82 Asymptomatic ventricular arrhythmias (...) in patients with congestive heart failure are associated with increased rates of overall mortality and sudden death. Amiodarone is now used widely to prevent ventricular tachycardia and fibrillation. We conducted a trial to determine whether amiodarone can reduce overall mortality in patients with congestive heart failure and asymptomatic ventricular arrhythmias. We used a double-blind, placebo-controlled protocol in which 674 patients with symptoms of congestive heart failure, cardiac enlargement, 10

NEJM1995

74. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia

Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia Hohnloser S H, Klingenheben T, Singh B N Authors' objectives To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias (...) or the development of new arrhythmias, in particular torsade de pointes. Searching MEDLINE and Current Contents (Clinical Medicine) were searched from 1973 to June 1993 for English language papers, using keywords such as 'amiodarone', 'torsade de pointes', 'proarrhythmia' and 'aggravation of arrhythmia'. Manual searches of references in review articles were performed similarly. Study selection Study designs of evaluations included in the review Case reports, retrospective studies with at least 50 patients

DARE.1994

75. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) 7914611 1994 09 15 1994 09 15 2015 06 16 0140-6736 344 8921 1994 Aug 20 Lancet (London, England) Lancet Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) 493-8 In severe heart failure many deaths are sudden and are presumed (...) to be due to ventricular arrhythmias. The GESICA trial evaluated the effect of low-dose amiodarone on two-year mortality in patients with severe heart failure. Our prospective multicentre trial included 516 patients on optimal standard treatment for heart failure. Patients were randomised to 300 mg/day amiodarone (260) or to standard treatment (256). Intention-to-treat analysis showed 87 deaths in the amiodarone group (33.5%) compared with 106 in the control group (41.4%) (risk reduction 28%; 95% CI 4

Lancet1994

76. Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone.

Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. 2569105 1989 09 01 1989 09 01 2015 06 16 0140-6736 2 8658 1989 Aug 05 Lancet (London, England) Lancet Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. 302-5 In a randomised cross-over study, six patients with recurrent sustained ventricular tachycardia (VT) were treated with 3 regimens--amiodarone, amiodarone plus metoprolol (...) , and amiodarone plus xamoterol. All patients had poor left ventricular function and were resistant to multiple drugs. Xamoterol (a partial beta-agonist) was more effective than metoprolol as adjuvant therapy to amiodarone in the control of recurrent sustained ventricular arrhythmias and was not associated with any clinical deterioration of ventricular function. Xamoterol was also more effective than metoprolol for suppression of VT at programmed stimulation and as effective as metoprolol for suppression of VT

Lancet1989